Company: LIMN
Filing Date: 2025-01-15
Form Type: CORRESP
Source: 0001104659-25-003831
Chunk: 2

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-15
Form: CORRESP
Chunk 2
---
 Form S-4.

6. Please remove suggestions that your product candidate, IBA-101, has a promising “safety profile,” both here and throughout your prospectus. Determinations of safety and efficacy are in the sole jurisdiction of the FDA and given the pre-clinical stage of your current product candidate, these statements appear to be pre-mature. Also, where you continue to discuss your toxicity-related experiments, such as on page 185, please revise to indicate whether these results were statistically meaningful.

:

In response to the Staff’s comment, the Company
has revised the disclosure on pages 12 and 115 of the Form S-4. The Company has also revised the disclosure on pages 188
and 189 of the Form S-4 to provide additional disclosure requested by the Staff.

7. Please revise your statement here and throughout the prospectus that Liminatus’ anti- CD47 antibody, IBA-101, potentially positions the company as a “frontrunner” in the CD47 space. Given the current stage of development of this product candidate such statements appear to be pre-mature.

:

In response to the Staff’s comment, the Company
has revised the disclosure on pages 13 and 116 of the Form S-4.

Tamika Sheppard

Tim Buchmiller

U.S. Securities & Exchange Commission

January 15, 2025

Page 3

Termination, page 4

8. We note that Section 4.1(b) of the Business Combination Agreement has been amended so that it is now a condition to closing that Iris Acquisition Corporation shall have received “an acknowledgement from Viral Gene stating that the obligations of the parties thereto, including ParentCo and the Company, under, or pursuant to, the Viral Gene Assignment have been satisfied or terminated and that no obligations of any party thereto, including ParentCo and the Company, under the Viral Gene Assignment remain outstanding.” Please update your disclosure for this new condition to closing, indicate whether the acknowledgment has been received, and, if not, whether this condition to closing is waivable. If this condition is waivable, please include appropriate risk factor disclosure.

:

In response to the Staff’s comment, the Company
has revised the disclosure on page 4 of the Form S-4.

Lock-Up Agreement, page 6

9. We note your disclosure that on August 9, 2024, ParentCo and Sponsor agreed to grant a waiver of the lock-up restrictions contained in the